Lv51
1140 积分 2021-01-12 加入
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study
1小时前
待确认
A Review of Phase III and Long‐Term Data for Deucravacitinib for Plaque Psoriasis
1天前
待确认
Outcomes of PASI and PASI components in two phase 3 trials of deucravacitinib in patients with moderate to severe plaque psoriasis
1天前
待确认
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index
22天前
已完结
Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis
22天前
已完结
Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients
1个月前
已关闭
New Topical and Systemic Treatments for Atopic Dermatitis
1个月前
已关闭
Stapokibart Rapidly and Consistently Improves the Clinical Signs Across All Body Regions in Adults With Moderate‐to‐Severe Atopic Dermatitis
1个月前
已完结
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial
1个月前
已完结
The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects
2个月前
已完结
皖公网安备34019202002308
